
Bart Hens

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4421151/publications.pdf Version: 2024-02-01



RADT HENG

#	Article	IF	CITATIONS
1	Dissolution Challenges Associated with the Surface pH of Drug Particles: Integration into Mechanistic Oral Absorption Modeling. AAPS Journal, 2022, 24, 17.	2.2	9
2	Exploring the Predictive Power of the <i>In Situ</i> Perfusion Technique towards Drug Absorption: Theory, Practice, and Applications. Molecular Pharmaceutics, 2022, 19, 749-762.	2.3	3
3	Exploring the Impact of Intestinal Fluid Components on the Solubility and Supersaturation of Danazol. Journal of Pharmaceutical Sciences, 2021, 110, 2479-2488.	1.6	2
4	Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare. Frontiers in Medicine, 2021, 8, 480706.	1.2	2
5	An In Vivo Predictive Dissolution Methodology (iPD Methodology) with a BCS Class IIb Drug Can Predict the In Vivo Bioequivalence Results: Etoricoxib Products. Pharmaceutics, 2021, 13, 507.	2.0	7
6	Biopredictive in vitro testing methods to assess intestinal drug absorption from supersaturating dosage forms. Journal of Drug Delivery Science and Technology, 2020, 56, 101275.	1.4	6
7	Mechanistic Deconvolution of Oral Absorption Model with Dynamic Gastrointestinal Fluid to Predict Regional Rate and Extent of GI Drug Dissolution. AAPS Journal, 2020, 22, 3.	2.2	6
8	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2â^'infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26955-26965.	3.3	240
9	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	1.9	18
10	Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products. AAPS Journal, 2020, 22, 113.	2.2	9
11	Translational Modeling Strategies for Orally Administered Drug Products: Academic, Industrial and Regulatory Perspectives. Pharmaceutical Research, 2020, 37, 95.	1.7	8
12	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-Cola® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). Pharmaceutics, 2020, 12, 566.	2.0	8
13	Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 150, 66-76.	2.0	11
14	A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP. Pharmaceutics, 2020, 12, 74.	2.0	49
15	Measurement of fasted state gastric antral motility before and after a standard bioavailability and bioequivalence 240 mL drink of water: Validation of MRI method against concomitant perfused manometry in healthy participants. PLoS ONE, 2020, 15, e0241441.	1.1	8
16	Title is missing!. , 2020, 15, e0241441.		0
17	Title is missing!. , 2020, 15, e0241441.		0

BART HENS

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0241441.		0
20	Title is missing!. , 2020, 15, e0241441.		0
21	Title is missing!. , 2020, 15, e0241441.		0
22	Integrating Drug- and Formulation-Related Properties With Gastrointestinal Tract Variability Using a Product-Specific Particle Size Approach: Case Example Ibuprofen. Journal of Pharmaceutical Sciences, 2019, 108, 3842-3847.	1.6	21
23	"Development of Fixed Dose Combination Products―Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS Journal, 2019, 21, 75.	2.2	7
24	Exploring Bioequivalence of Dexketoprofen Trometamol Drug Products with the Gastrointestinal Simulator (GIS) and Precipitation Pathways Analyses. Pharmaceutics, 2019, 11, 122.	2.0	17
25	The mechanisms of pharmacokinetic food-drug interactions – A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	1.9	224
26	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 70-83.	2.0	91
27	Application of a Dynamic Fluid and pH Model to Simulate Intraluminal and Systemic Concentrations of a Weak Base in GastroPlusâ"¢. Journal of Pharmaceutical Sciences, 2019, 108, 305-315.	1.6	32
28	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. AAPS Journal, 2018, 20, 57.	2.2	19
29	Evaluation and optimized selection of supersaturating drug delivery systems of posaconazole (BCS) Tj ETQq1 1 Journal of Pharmaceutical Sciences, 2018, 115, 258-269.	0.784314 1.9	rgBT /Overlo 43
30	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans—Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	2.3	12
31	Mass Transport Analysis of the Enhanced Buffer Capacity of the Bicarbonate–CO ₂ Buffer in a Phase-Heterogenous System: Physiological and Pharmaceutical Significance. Molecular Pharmaceutics, 2018, 15, 5291-5301.	2.3	23
32	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humans—Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467.	2.3	21
33	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 162-174.	2.0	24
34	Formulation predictive dissolution (fPD) testing to advance oral drug product development: An introduction to the US FDA funded â€~21st Century BA/BE' project. International Journal of Pharmaceutics, 2018, 548, 120-127.	2.6	41
35	Persistent Threats by Persistent Pollutants: Chemical Nature, Concerns and Future Policy Regarding PCBs—What Are We Heading For?. Toxics, 2018, 6, 1.	1.6	68
36	Summary of the In Vivo Predictive Dissolution (iPD) - Oral Drug Delivery (ODD) Conference 2018. Dissolution Technologies, 2018, 25, 50-53.	0.2	2

BART HENS

#	Article	IF	CITATIONS
37	Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 467-474.	0.7	11
38	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	2.6	81
39	<i>In Silico</i> Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole. Molecular Pharmaceutics, 2017, 14, 4321-4333.	2.3	59
40	Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for <i>in Vivo</i> Dissolution and Absorption of Ionizable Drugs. Molecular Pharmaceutics, 2017, 14, 4281-4294.	2.3	94
41	What can we learn from 'dioxin incidents'?. International Journal of Environment and Pollution, 2016, 60, 34.	0.2	8
42	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. Journal of Pharmaceutical Sciences, 2016, 105, 2677-2684.	1.6	92
43	Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Field–Flow Fractionation/Multiangle Laser Light Scattering. Journal of Pharmaceutical Sciences, 2016, 105, 2832-2839.	1.6	36
44	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. Journal of Pharmaceutical Sciences, 2016, 105, 2904-2912.	1.6	43
45	Drug disposition before and after gastric bypass: fenofibrate and posaconazole. British Journal of Clinical Pharmacology, 2016, 82, 1325-1332.	1.1	24
46	In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. International Journal of Pharmaceutics, 2016, 515, 352-358.	2.6	29
47	What can we learn from 'dioxin incidents'?. International Journal of Environment and Pollution, 2016, 60, 34.	0.2	1
48	Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. European Journal of Pharmaceutical Sciences, 2015, 77, 40-47.	1.9	82
49	A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption. European Journal of Pharmaceutical Sciences, 2014, 57, 322-332.	1.9	159
50	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. European Journal of Pharmaceutical Sciences, 2014, 63, 233-242.	1.9	63
51	Supersaturation in human gastric fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 184-189.	2.0	57